A detailed history of Tang Capital Management LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Tang Capital Management LLC holds 874,076 shares of BCAB stock, worth $1.5 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
874,076
Previous 1,374,076 36.39%
Holding current value
$1.5 Million
Previous $1.88 Million 18.28%
% of portfolio
0.13%
Previous 0.23%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.17 - $2.05 $585,000 - $1.02 Million
-500,000 Reduced 36.39%
874,076 $1.54 Million
Q2 2024

Aug 14, 2024

SELL
$1.37 - $3.92 $137,000 - $392,000
-100,000 Reduced 6.78%
1,374,076 $1.88 Million
Q1 2024

May 15, 2024

SELL
$1.88 - $3.46 $1.97 Million - $3.63 Million
-1,050,000 Reduced 41.6%
1,474,076 $5.07 Million
Q4 2023

Feb 14, 2024

SELL
$1.27 - $3.18 $1.46 Million - $3.66 Million
-1,150,000 Reduced 31.3%
2,524,076 $6.21 Million
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $141,500 - $193,500
50,000 Added 1.38%
3,674,076 $11 Million
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $1.15 Million - $4.13 Million
500,000 Added 16.0%
3,624,076 $9.71 Million
Q4 2022

Feb 14, 2023

SELL
$6.29 - $11.01 $1.57 Million - $2.74 Million
-248,924 Reduced 7.38%
3,124,076 $25.8 Million
Q2 2022

Aug 15, 2022

BUY
$2.13 - $5.38 $4.84 Million - $12.2 Million
2,273,000 Added 206.64%
3,373,000 $9.61 Million
Q1 2022

May 16, 2022

BUY
$4.38 - $18.78 $3.51 Million - $15.1 Million
802,086 Added 269.23%
1,100,000 $5.5 Million
Q4 2021

Feb 14, 2022

BUY
$19.0 - $30.95 $5.66 Million - $9.22 Million
297,914 New
297,914 $5.85 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Tang Capital Management LLC Portfolio

Follow Tang Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tang Capital Management LLC with notifications on news.